The Impact of Contraception on Postpartum Weight Loss

University of Pennsylvania100 enrolled

Overview

This is a prospective mixed methods study to assess weight changes in women randomized to receive Implanon ® or Depo Provera® (DMPA) immediately postpartum compared to women who choose non-hormonal contraception or no contraception immediately postpartum. After enrollment, subjects return for a visit at 3, 6 and 12 months postpartum to be asked a series of questions, take a pregnancy test, and be weighed. Total length of participation for each subject is 1 year or until pregnancy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

100

Conditions

Weight

Interventions

DMPA immediately postpartumDRUG

DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.

Implanon immediately postpartumDRUG

Implanon ® is a subdermal implant that contains 68mg of etonogestrel.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * English speaking * Aged 18-45 at enrollment (inclusive) * Immediately postpartum of a live singleton infant, 37 weeks gestation, at HUP * Desiring to delay another pregnancy for 6 months * Willing and able to follow the study protocol Exclusion Criteria: * Breastfeeding during study participation * Plans for relocation outside of Philadelphia in the next six months * Plans for use of weight loss medication or diet pills in the next six months * Women who wish to start Implanon ® or DMPA prior to discharge but who do not want to be randomized. 5. Issues or concerns in the judgment of the investigator that may compromise the safety of the subject or confound the reliability of compliance and information acquired in this study

Locations (1)

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Weight

Weight will be measured at 6 months postpartum. Percent weight change will be compared amongst the groups

Time frame: 6 months from postpartum (baseline)

Secondary Outcomes

Pregnancy Rate

The secondary outcome variable is pregnancy rate. Pregnancy testing will occur at 3, 6 and 12 months postpartum or at any time that a participant felt that she might be pregnant.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.